Biotechnology
MDPen Launches Corrective Microneedling™: Advanced Skin Rejuvenation Technology
MDPen introduces a cutting-edge microneedling technique that creates up to 324,000 microchannels per minute, offering comprehensive skin rejuvenation solutions for practitioners and patients across multiple skin concerns.
Canadian Firms Unveil Rapid Drug Residue Detection Device to Enhance Public Safety
Kaimi Biotech and Scenesafe partner to introduce Unow™, a portable testing device capable of quickly identifying trace drug residues across multiple sectors in Canada. The technology aims to improve safety protocols in law enforcement, healthcare, and property management.
Creative Biolabs Unveils Advanced Bispecific Antibody Platform at Industry Conference
Creative Biolabs demonstrates cutting-edge bispecific antibody technology with potential to revolutionize cancer immunotherapy, showcasing customized development capabilities and innovative research approaches.
Calidi Biotherapeutics Appoints Experienced Life Science Leader Eric Poma as New CEO
Calidi Biotherapeutics has named Dr. Eric Poma as its new Chief Executive Officer, bringing over 30 years of life science expertise to guide the company's innovative cancer therapy development strategy.
Nutriband Expands Pharma Footprint with Strategic Partnerships
Nutriband Inc. strengthens its market position through strategic alliances with Charlotte FC and Kindeva Drug Delivery, focusing on its innovative abuse-deterrent transdermal drug delivery technology.
Soligenix Advances Phase 3 Trial for Cutaneous T-Cell Lymphoma Treatment, Zacks Report Shows Promise
Soligenix continues enrollment in its Phase 3 HyBryte trial for cutaneous T-cell lymphoma, with Zacks Research highlighting the trial's high potential for success and anticipated topline results in 2026.
Calidi Biotherapeutics Advances Cancer Immunotherapy Platform, Reduces Quarterly Losses
Calidi Biotherapeutics has made significant progress in its oncology research, receiving FDA clearance for a stem cell-based immunotherapy and presenting promising data on its Redtail virotherapy platform while simultaneously reducing operational expenses.
Creative Biolabs Advances Antibody Engineering with Innovative Glycosylation Technology
Creative Biolabs has developed a sophisticated analytical platform for monoclonal antibody glycan profiling, enhancing therapeutic antibody effectiveness through precise Fc region modifications. These technological improvements could significantly impact biopharmaceutical drug development.
Tevard's tRNA Therapy Offers Promising Approach to Duchenne Muscular Dystrophy Treatment
Tevard Biosciences demonstrated a breakthrough in treating Duchenne Muscular Dystrophy by restoring full-length dystrophin protein using suppressor tRNA therapy, potentially offering hope for patients with nonsense mutations.
SeaStar Medical Achieves Six FDA Breakthrough Device Designations, Promising New Hope for Critical Care Patients
SeaStar Medical has secured six FDA Breakthrough Device Designations for its Selective Cytopheretic Device (SCD) therapy, targeting life-threatening conditions with limited treatment options. These designations highlight the potential to transform care for patients with acute kidney injury, inflammatory responses, and other critical health challenges.
Oragenics Receives Australian Approval for Phase II Concussion Trial
Biotechnology company Oragenics has secured regulatory approval to launch a Phase II clinical trial for ONP-002, a novel intranasal therapy targeting mild traumatic brain injury. The trial represents a potential advancement in treating concussions with a non-invasive approach.
Creative Biolabs Showcases AI-Powered Drug Discovery and Innovative Antibody Technology at BioPharma Expo
Creative Biolabs demonstrates technological prowess through an AI-powered drug discovery platform, a global scholarship program for life science students, and a groundbreaking webinar on dual-function antibody technology that could revolutionize cancer treatment.
Oragenics to Discuss Promising Concussion Treatment in Upcoming Webinar
Biotechnology company Oragenics will host a management webinar to highlight its lead intranasal therapy ONP-002, currently in Phase IIa trials for mild traumatic brain injury, potentially addressing an unmet medical need in concussion treatment.
Calidi Biotherapeutics Unveils Promising Cancer Treatment Platform with Broad Therapeutic Potential
Calidi Biotherapeutics has demonstrated preclinical success with its RTNova platform, showing the ability to deliver gene-therapy payloads and kill over 60 tumor cell lines, potentially transforming cancer treatment approaches.
Diplomatic Trade Acquires Major Stake in Turkish Pharmaceutical Company, Targets $300M IPO
Diplomatic Trade Ltd and its investment arm have secured a 49% equity position in a Turkish pharmaceutical company, with plans to launch a bio-manufacturing facility in the UAE and pursue a potential $300 million IPO in late 2025.
ABVC BioPharma Secures Japanese Patent for Innovative Depression Treatment
ABVC BioPharma has obtained a Japanese patent for its botanical-based Major Depressive Disorder treatment ABV-1504, expanding its global intellectual property portfolio and positioning the company for potential market entry in Japan's robust pharmaceutical landscape.
Scinai Immunotherapeutics Turns Financial Corner with $4.8 Million Net Gain
Biotechnology company Scinai Immunotherapeutics reports a significant financial turnaround in 2024, transforming a previous year's loss into a net gain through strategic financial management and early revenue generation.
Telomir Pharmaceuticals Advances Neurological Research with Novel Cellular Restoration Candidate
Telomir Pharmaceuticals reveals promising preclinical data for Telomir-1, a small molecule targeting cellular decline, with potential applications in autism spectrum disorder and rare neurological conditions. The research demonstrates potential breakthrough in understanding age-related cellular deterioration.
Soligenix CEO Highlights Rare Disease Therapeutics and Public Health Solutions Strategy
Soligenix's CEO discusses the company's two-pronged business model focused on rare disease treatments and public health solutions, emphasizing significant government funding and promising clinical trial developments.
GeoVax Secures New Patent for Innovative Cancer Treatment Approach
GeoVax Labs has received a Notice of Allowance for a patent describing a novel triple-combination cancer therapy strategy targeting solid tumors with potential to minimize systemic toxicity and enhance treatment effectiveness.
Pacylex Pharmaceutical Explores N-myristoyltransferase Inhibitors as Potential ADC Cancer Therapies
Pacylex Pharmaceuticals is presenting innovative research on N-myristoyltransferase (NMT) inhibitors as potential payloads for antibody drug conjugates (ADCs), highlighting promising early clinical results in cancer treatment across multiple tumor types.
Aditxt Advances ADI-100 Therapeutic Development with Leadership Update
Aditxt Inc. continues to develop innovative immune-modulating therapies through its ADI-100 therapeutic candidate, highlighting ongoing progress in its health innovation platform. The company's strategic approach involves collaborative research and potential expansion into multiple health domains.
GeoVax Advances COVID-19, Cancer, and Biosecurity Vaccine Platforms Despite BARDA Contract Setback
GeoVax Labs reports significant progress across multiple vaccine development programs, including a multi-antigen COVID-19 vaccine for immunocompromised patients, an oncology treatment for head and neck cancer, and a Mpox/smallpox vaccine addressing global biosecurity needs.
TransCode Therapeutics Advances RNA Cancer Therapy in Phase 1a Trial, Shows Promising Early Results
TransCode Therapeutics reports encouraging progress in its Phase 1a trial of TTX-MC138, an RNA-based cancer therapy targeting microRNA-10b, with initial data suggesting potential effectiveness in treating metastatic tumors.
Scinai Immunotherapeutics to Discuss Potential Breakthrough Treatment for Rare Skin Disorders
Scinai Immunotherapeutics will host a webinar to explore the therapeutic potential of PC111, a novel monoclonal antibody targeting rare skin conditions like Pemphigus Vulgaris and SJS/TEN, following its recent acquisition of Pincell.
Rapid Diagnostic Test Developed for Bacterial Meningitis
Researchers at Amsterdam University Medical Center have created a new diagnostic test that can quickly and accurately detect bacterial meningitis by measuring protein levels in cerebrospinal fluid, potentially improving patient outcomes through faster diagnosis.
Calidi Biotherapeutics Advances Cancer Treatment with Innovative Gene Therapy Platform
Calidi Biotherapeutics has revealed promising preclinical results for its RTNova platform, offering a potential breakthrough in targeted gene therapy for cancer treatment amid rising global cancer rates.
Nutriband Advances Abuse-Deterrent Transdermal Drug Technology, Eyes 2025 Commercialization
Nutriband is positioning itself for potential market expansion by developing innovative abuse-deterrent transdermal pharmaceutical products with projected peak annual sales exceeding $330 million for its Fentanyl and Buprenorphine patches.
Fifty 1 Labs Launches BioSentry Division, Appoints New CEO to Advance Biohazard Detection Technology
Fifty 1 Labs has appointed Michael Lawson as CEO and established a new BioSentry Division focused on developing advanced real-time sensor systems for detecting biological, chemical, and environmental threats across multiple sectors.
Quantumzyme Addresses OTC Markets Caveat Emptor Status and Unauthorized Promotional Activity
Biotechnology firm Quantumzyme is taking swift action to address its Caveat Emptor designation from OTC Markets and denounce unauthorized promotional text messages, demonstrating its commitment to regulatory compliance and market integrity.